Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 May;52(5):372–375. doi: 10.1136/jcp.52.5.372

Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.

R P Zweemer 1, P A Shaw 1, R M Verheijen 1, A Ryan 1, A Berchuck 1, B A Ponder 1, H Risch 1, J R McLaughlin 1, S A Narod 1, F H Menko 1, P Kenemans 1, I J Jacobs 1
PMCID: PMC1023075  PMID: 10560359

Abstract

BACKGROUND: Mutations in the BRCA1 or BRCA2 genes are responsible for up to 95% of hereditary ovarian cancer cases. Both genes function as tumour suppressor genes, and development of a cancer is thought to require an accumulation of somatic genetic events in addition to the inherited germline predisposition. It is unknown whether these somatic events in BRCA associated ovarian cancer are similar to or distinct from those in sporadic cases. The most frequent somatic genetic event in ovarian cancer is a mutation of the p53 gene. AIM: To study the role of p53 in hereditary ovarian cancer, by analysing accumulation of the p53 protein in ovarian cancers which occurred in BRCA1 or BRCA2 germline mutation carriers and comparing the results with a panel of ovarian cancers from patients who tested negative for both BRCA1 and BRCA2. METHODS: The study group consisted of 39 ovarian cancer patients in whom a BRCA mutation had been confirmed previously. p53 Immunohistochemistry was performed on archival tissue using a standard microwave antigen retrieval technique. The rate of p53 accumulation was compared with 40 ovarian cancer cases who tested negative for BRCA1 and BRCA2 germline mutations. RESULTS: P53 Accumulation was similar in BRCA related ovarian cancers and BRCA negative controls. Overall 27 of 39 BRCA1 or BRCA2 positive cases (69%) had evidence of p53 accumulation, compared with 24 of 40 invasive ovarian cancer cases (60%) which tested negative for BRCA1 and BRCA2 germline mutations. BRCA1 related ovarian cancers showed p53 accumulation in 22 of 30 cases (73%); p53 accumulation was present in five of nine BRCA2 related ovarian cancers. CONCLUSIONS: In addition to germline BRCA1 and BRCA2 mutations, somatic p53 alterations leading to p53 accumulation are an important event in hereditary ovarian cancer and are as frequent as in non-BRCA-related ovarian cancer.

Full text

PDF
372

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auranen A., Grénman S., Kleml P. J. Immunohistochemically detected p53 and HER-2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas. Cancer. 1997 Jun 1;79(11):2147–2153. doi: 10.1002/(sici)1097-0142(19970601)79:11<2147::aid-cncr12>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  2. Berchuck A., Kohler M. F., Marks J. R., Wiseman R., Boyd J., Bast R. C., Jr The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):246–252. doi: 10.1016/s0002-9378(94)70414-7. [DOI] [PubMed] [Google Scholar]
  3. Casey G., Lopez M. E., Ramos J. C., Plummer S. J., Arboleda M. J., Shaughnessy M., Karlan B., Slamon D. J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996 Nov 7;13(9):1971–1981. [PubMed] [Google Scholar]
  4. Crook T., Crossland S., Crompton M. R., Osin P., Gusterson B. A. p53 mutations in BRCA1-associated familial breast cancer. Lancet. 1997 Aug 30;350(9078):638–639. doi: 10.1016/S0140-6736(05)63327-2. [DOI] [PubMed] [Google Scholar]
  5. Easton D. F., Ford D., Bishop D. T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271. [PMC free article] [PubMed] [Google Scholar]
  6. Easton D. F., Steele L., Fields P., Ormiston W., Averill D., Daly P. A., McManus R., Neuhausen S. L., Ford D., Wooster R. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997 Jul;61(1):120–128. doi: 10.1086/513891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ford D., Easton D. F., Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995 Dec;57(6):1457–1462. [PMC free article] [PubMed] [Google Scholar]
  8. Kerns B. J., Jordan P. A., Moore M. B., Humphrey P. A., Berchuck A., Kohler M. F., Bast R. C., Jr, Iglehart J. D., Marks J. R. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem. 1992 Jul;40(7):1047–1051. doi: 10.1177/40.7.1607637. [DOI] [PubMed] [Google Scholar]
  9. Kohler M. F., Marks J. R., Wiseman R. W., Jacobs I. J., Davidoff A. M., Clarke-Pearson D. L., Soper J. T., Bast R. C., Jr, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst. 1993 Sep 15;85(18):1513–1519. doi: 10.1093/jnci/85.18.1513. [DOI] [PubMed] [Google Scholar]
  10. Kupryjańczyk J., Thor A. D., Beauchamp R., Merritt V., Edgerton S. M., Bell D. A., Yandell D. W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961–4965. doi: 10.1073/pnas.90.11.4961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  12. Rubin S. C., Benjamin I., Behbakht K., Takahashi H., Morgan M. A., LiVolsi V. A., Berchuck A., Muto M. G., Garber J. E., Weber B. L. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996 Nov 7;335(19):1413–1416. doi: 10.1056/NEJM199611073351901. [DOI] [PubMed] [Google Scholar]
  13. Skilling J. S., Sood A., Niemann T., Lager D. J., Buller R. E. An abundance of p53 null mutations in ovarian carcinoma. Oncogene. 1996 Jul 4;13(1):117–123. [PubMed] [Google Scholar]
  14. Stratton J. F., Gayther S. A., Russell P., Dearden J., Gore M., Blake P., Easton D., Ponder B. A. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997 Apr 17;336(16):1125–1130. doi: 10.1056/NEJM199704173361602. [DOI] [PubMed] [Google Scholar]
  15. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. doi: 10.1038/378789a0. [DOI] [PubMed] [Google Scholar]
  16. Zweemer R. P., Verheijen R. H., Gille J. J., van Diest P. J., Pals G., Menko F. H. Clinical and genetic evaluation of thirty ovarian cancer families. Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):85–90. doi: 10.1016/s0002-9378(98)70632-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES